MTOR and Ehlers-Danlos syndrome, musculocontractural type: As compared to PDTCs, ATCs had a higher frequency of mutations in TP53 (73%), TERT promoter (73%), PI3K/AKT/mTOR pathway effectors (39%), SWI/SNF subunits (36%), and histone methyltransferases (24%) and 9% of ATCs had EIF1AX mutations.